Team - Sound Bioventures

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

We lead, co-lead or follow

Team

As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making.

Read more about the Team

Strategy & Approach

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

Read more about Strategy & Approach

Why the name Sound Bioventures?

Our investment firm started as a Danish-Swedish project with our Danish founder Casper Breum and our Swedish founder Johan Kördel living on either side of the stretch of water between Denmark and Sweden connecting the North and Baltic seas, called “the Sound”. The name is derived from the Scandinavian Öresund (SE) or Øresund (DK). The Sound has always been one of the world’s busiest shipping lanes with approximately 40.000 ships passing through annually. The SE/DK Sound or Greater Copenhagen region is referred to as Medicon Valley and is, like the shipping lane, arguably the busiest in Scandinavia. When our American founder Bibhash Mukhopadhyay joined, our proposition to our investors and portfolio companies took on an expanded global perspective and footprint, spanning an even bigger water passage, the Atlantic Ocean.-“a super sized version of the Sound”! Sound does of course also stand for financially robust investments as well as investments that lead to a healthy body and mind.
Read more about Sound Bioventures »

Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases

Cambridge, MA, November 15, 2022 Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company is strengthening its Scientific Advisory Board (SAB) with the appointments of James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D. Artax Biopharma has an …